Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 25 Apr 23 EFFECT Notice of effectiveness
- 17 Apr 23 POS AM Prospectus update (post-effective amendment)
- 16 Dec 20 424B5 Prospectus supplement for primary offering
- 20 Nov 20 EFFECT Notice of effectiveness
- 13 Nov 20 POS AM Prospectus update (post-effective amendment)
- 2 Oct 20 424B5 Prospectus supplement for primary offering
- 16 Jun 20 EFFECT Notice of effectiveness
- 11 Jun 20 S-3/A Shelf registration (amended)
-
10 Jan 20 S-3 Shelf registration
SIOX similar filings
Filing view
External links
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” in this Registration Statement (Form S-3) and related prospectus of Axovant Gene Therapies Ltd. for the registration of common shares, preference shares, debt securities, and warrants and to the incorporation by reference therein of our report dated June 11, 2019, with respect to the consolidated financial statements of Axovant Gene Therapies Ltd., included in its Annual Report (Form 10-K) for the year ended March 31, 2019, filed with the Securities and Exchange Commission.
/s/Ernst & Young LLP
Iselin, New Jersey
January 10, 2020